Bar-OrANicholasJFengJ, et al. Exploring the clinical utility of neurofilament light chain assays in multiple sclerosis management. Neurol Neuroimmunol Neuroinflammation2025; 12: e200427.
2.
ChitnisTQureshiFGehmanVM, et al. Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis. Nat Commun2024; 15: 4297.
3.
FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [online]. Silver Spring, MD: Food and Drug Administration (US), 2016, http://www.ncbi.nlm.nih.gov/books/NBK326791/ (accessed 25 November 2025).
4.
FreedmanMSGnanapavanSBoothRA, et al. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. Ebiomedicine2024; 101: 104970.
5.
BenkertPMeierSSchaedelinS, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: A retrospective modelling and validation study. Lancet Neurol2022; 21: 246–257.
6.
PepeMSJanesHLongtonG, et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol2004; 159: 882–890.
7.
FoxRJCreeBACde SèzeJ, et al. Temporal relationship between serum neurofilament light chain and radiologic disease activity in patients with multiple sclerosis. Neurology2024; 102: e209357.
8.
FitzgeraldKCSotirchosESSmithMD, et al. Contributors to serum NfL levels in people without neurologic disease. Ann Neurol2022; 92(4): 688–698.
9.
SotirchosESHuCSmithMD, et al. Agreement between published reference resources for neurofilament light chain levels in people with multiple sclerosis. Neurology2023; 101: e2448–e2453.
10.
JaniaudPZeccaCSalmenA, et al. MultiSCRIPT-Cycle 1—A pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: A study protocol for a randomized clinical trial. Trials2024; 25: 607.
